While demand for GLP-1s remains high, reports show that medication persistence is surprisingly low. GLP-1 discontinuation can be a concern for payers and patients alike, as clinical trial results indicate that people may regain a considerable amount of weight once they stop the GLP-1. However, does weight health progress have to stop when people discontinue their GLP-1? Is it possible that virtual programs—which have long been in the business of weight health—offer tailored tools and support that could lead to successful weight maintenance?